FWCM
TVRD

Ferguson Wellman Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Ferguson Wellman Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-966
Closed -$10.7K – 366
2024
Q3 		$10.7K Buy
+966
New +$11.3K ﹤0.01% 355

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ferguson Wellman Capital Management's TVRD Position: Q4 2024 in Review

Ferguson Wellman Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 966 shares — an estimated $10.7K sold.

Ferguson Wellman Capital Management first reported a position in TVRD in Q3 2024 and held it in 1 quarter. The position peaked at $10.7K in Q3 2024. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Ferguson Wellman Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ferguson Wellman Capital Management sold 966 Tvardi Therapeutics shares in Q4 2024, an estimated $10.7K.
  • Ferguson Wellman Capital Management first reported a position in Tvardi Therapeutics in Q3 2024 and held it in 1 quarter.
  • Ferguson Wellman Capital Management's Tvardi Therapeutics position peaked at $10.7K in Q3 2024.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Ferguson Wellman Capital Management's 13F filing for Q4 2024, filed 29 Jan 2025.